At Pelago Bioscience, we’re here to help you make faster, better-informed decisions in drug discovery. In 2010, our founders began to develop our proprietary CETSA® (Cellular Thermal Shift Assay) technology, publishing a seminal research paper in Science 2013. Since then, Pelago Bioscience has become the leading CRO providing actionable, biologically relevant insights at the pre-clinical stage.Unlike traditional methods, CETSA gives you a reliable picture of drug-target interactions, ensuring that what you see in cells translates to patients. Our services rest on four pillars: • Certainty in Biological Relevance: CETSA’s physiological approach helps minimize late-stage risks. • Fast & Early Confidence: We deliver actionable insights in just 10 days-10 weeks (service dependent), eliminating unnecessary complexities so you can make decisions faster. • Insights & Progress: Our data supports compound prioritization and predicts future research steps, reducing project costs. • Extended Team Support: We work as your dedicated partner, designing fit-for-purpose studies that align with your goals. With Pelago Bioscience, you gain more than just data; you gain a trusted partner in your discovery journey.
Looking for a particular Pelago Bioscience AB employee's phone or email?
The Pelago Bioscience AB annual revenue was $2 million in 2026.
Michael Dabrowski is the CEO of Pelago Bioscience AB.
52 people are employed at Pelago Bioscience AB.
Pelago Bioscience AB is based in Solna, Stockholm.
The NAICS codes for Pelago Bioscience AB are [541, 5417, 54].
The SIC codes for Pelago Bioscience AB are [28, 283].